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Aim: To determine the association of peroxisome proliferator activated receptor gamma 
coactivator 1 Gly482Ser variant with components of metabolic syndrome.  
Materials and Methods: A systematic search was carried out using Web of Science, PubMed, 
EMBASE and the Cochrane library using the key words:  Peroxisome proliferator activator 
receptor gamma coactivator 1, PPARGC1A, PGC-1, PGC-1alpha, and PGC1alpha alone or with 
polymorphism, Gly482Ser and rs8192678.   
Results:  Data from 19 articles generated 28 separate data sets.  Under the recessive model fasting 
plasma glucose was significantly lower in AA genotypes when compared to GG+GA in the total 
sample group and in non-Asian group (p<0.001). The AA genotype showed significantly lower 
levels of total cholesterol compared to GG+GA genotype using the recessive model with the non-
Asian group (p<0.05).  Under the dominant model, body mass index of the GG genotype was 
significantly higher in Asian subgroups (p<0.05)  


















Metabolic syndrome is the combined presentation of at least three of the following criteria: 
impaired fasting glucose, increased waist circumference, elevated blood pressure (BP), elevated 
triglycerides and/or elevated cholesterol [1] (Supplementary Table 1).  In this study we will 
investigate the association of components of metabolic syndrome with a genetic variant 
(Gly482Ser) of the peroxisome proliferator activated receptor co-activator 1A (PPARGC1A).  
PPARGC1A interacts with PPAR gamma and this facilitates interaction with multiple 
transcription factors [2].  PPARGC1A plays a vital role, directly or indirectly in lipid metabolism 
and it is responsible for the activation of farnesoid X receptor (FXR), which decreases the level of 
triglycerides in the liver [3]. It also regulates the activity of the human hepatic lipase gene (LIPC) 
which is involved in lipid metabolism [4]. Furthermore, the expression of PPARGC1A in 
conjunction with its nuclear receptor, hepatocyte nuclear factor 4α (HNF4α) in the liver, increases 
a range of apolipoproteins that are responsible for triglyceride metabolism and very low-density 
lipoprotein (VLDL) metabolism [5].  PPARGC1A plays a major role in glucose transport in 
skeletal muscle [6] and pancreatic beta-cells [7] and co-activates the cholesterol 7-α-hydroxylase 
(CYP7A1) gene that encodes an enzyme essential for cholesterol metabolism [8,9].  
Located on chromosome 4p15.1 [10], the gene has a number of single nucleotide polymorphisms 
and in this study, we will explore the association of the missense variant Gly482Ser (rs8192678) 
of PPARGC1A with lipid profile and components of metabolic syndrome.  G is the major allele 
and A is the minor allele resulting in either glycine or serine amino acid residue at codon 482 of 
PPARGC1A.  The minor allele remains the same in most populations although the incidence 
within the Tongan population was over 70% [11].  This single nucleotide polymoyphism (SNP) 
lies within exon 8 of the gene and correlates with a region known to interact with PPAR  [10].  
The variant of this SNP influences the age-dependent expression of the PPARGC1A gene in 
skeletal muscle [12] and has also been associated with an increase in body fat mass, body fat ratio 
and body mass index (BMI) in Korean children [13] and in a Mexican population [14]. 
Hyperinsulinemia and an increased insulin resistance index in Chinese adults have also been noted 
[15].  Furthermore, there is an association of this genotype with excess weight gain in male 












[16] although the minor allele did not show any association with metabolic syndrome in Danish 
populations [17] or with body fat mass in an Indian population [18]. This allele has also been 
associated with hypertension in young individuals [19], high blood pressure in middle-aged men 
[20], and in men with Type 2 diabetes [21].  In contrast, a reduced risk of hypertension was 
observed in Danish Caucasians with the minor allele [22].  
 
The Gly482Ser polymorphism has been variously associated with lipid profile.  A reduced 
clearance of non-esterified fatty acid following a glucose load was reported in a European 
population with carriers of the Gly482Ser allele [23] while in a group of participants from the 
Middle East, total cholesterol and LDL level were found to be significantly higher in the wildtype 
[24].  Normoglycemic individuals from a Kurdish-Iranian population carrying the GA+AA 
genotype had lower levels of high-density lipoprotein (HDL) when compared to the GG genotype 
[25]. The levels of triglycerides (TG) in the pre-obese and obese group were significantly higher 
in wildtype genotypes of Gly482Ser under a dominant genetic model in a Mexican population 
[14].  Other studies such as, Andrulionyte et al, 2004 [26]; Zhang et al, 2007 [27]; Goyenechea et 
al, 2008 [28] and Niktin et al., 2010 [29] failed to show any significant difference in the levels of 
serum lipids in different genotype groups. Furthermore, due to conflicting results regarding 
Gly482Ser association with lipid levels and the importance of lipid profile and BMI in metabolic 
syndrome, this study aimed to assess if an association of the Gly482Ser polymorphism with lipid 
profile occurs.  A meta-analysis was conducted to address inconsistencies in the literature and to 
determine if further insights into the role of this variant can be derived in association with 
biochemical and metabolic characteristics.  The null hypothesis is therefore that the genetic variant 














2. Material and Methods 
2.1. Literature Search strategy 
The literature search strategy used is consistent with the guidelines outlined for the PRISMA [30]. 
An electronic search of the relevant published articles was conducted using web of science 
((http://apps.webofknowledge.com), PubMed (http://www.ncbi.nlm.nih.gov/pubmed), EMBASE 
and the Cochrane library. All original research articles published before 28/05/2018 were 
identified independently by two investigators using keywords specified in Supplementary Table 1, 
Any inconsistencies were discussed and articles selected according to the following inclusion 
criteria: full original research articles; published in the English language; conducted on humans; 
included genotype data related to rs8192678 (Gly482Ser) and corresponding biological data (TC, 
TG, HDL and LDL).  If these criteria were satisfied, corresponding biological data such as BMI 
and fasting plasma glucose (FPG) concentration were also included.  All articles represented either 
a case-control study, a cross-sectional study or an intervention study.  If an intervention study was 
included; only the data prior to the intervention were selected to avoid any bias from the 
intervention itself.  Articles were excluded if the reported data was presented as an interquartile 
range, contained data for those under 18 years of age or for those participants who were overtly 
taking statins.  In some studies, it is recognised that some participants may be taking a range of 
medications that are not reported and this may cause a degree of bias. 
2.2 Data extraction  
The following information was obtained from the selected peer reviewed articles: authors (articles 
recorded as first author et al., and year of publication) ethnicity of subjects, mean age, gender 
ratio, body mass index, sample size, mean value of high-density lipid (HDL), low density lipid 
(LDL), total cholesterol (TC), tri-glycerides (TG), and fasting plasm glucose (FPG) concentrations 
with the corresponding genotypes along with standard deviation.  In order to provide uniform 
measurement units, plasma lipids expressed in mg/dl were converted into mmol/L; the following 
conversion factor was used for HDL, LDL and TC; 1mmol/L is equivalent to 38.6mg/dl) for TG; 1 
mmol/L is equivalent to 88.5mg/L; and for glucose, 1mmol/L is equivalent to 18.01 mg/L.. 
If more than one data set was found within a single published article, they were treated as distinct 












size varied with each lipid variable as in the case of Vohl et al, (2005) [31], the lowest possible 
sample size was considered. When the lipid levels in three genotype groups were available, the 
mean and standard deviation of the two genotypes were combined to analyse the data under either 
the dominant or the recessive genetic models. The dominant genetic model assumes that the 
heterozygous and the homozygous form of the gene are treated as a single category and compared 
to homozygous dominant genotype while the recessive model compares the combined 
heterozygote and homozygous dominant forms to the homozygous recessive genotype.  The two 
data sets from Okauchi et al, 2008 [32] representing male and female subjects with or without type 
2 diabetes have been combined into one single group.  
2.3 Statistical analysis 
Meta-analysis was performed using STATA 13.1 (StataCorp. 2013. Stata Statistical Software: 
Release 13). The “Metan”: command of the STATA 13.1 was used for the present meta-analysis. 
All data are presented as mean ± SD and all the p-values were two-sided unless otherwise stated 
and a p-value ≤ 0.05 was regarded as statistically significant.  
The pooled weighted mean difference (WMD) with 95% confidence interval (CI) was used for the 
meta-analysis and the heterogeneity of the data was determined using the Chi-squared based Q-
test and I2 (0-100%) statistics.  The criteria for rejecting the null hypothesis of homogeneity was 
10% (p<0.1).  The Random effect model [33] was used when there was significant heterogeneity 
within the study data and the fixed effect model [34] was used when there was no significant 
heterogeneity. Heterogeneity was measured using Cochran’s Q. This follows a chi-squared 
distribution with k-1 degrees of freedom, where k is the number of studies carried out. 
Meta-analysis of the genotype data was initially carried out on the total selected data and 
subsequently separated to compare the data from Asian or Non-Asian sources.  In addition, the 
effect size of the biochemical data for each of the sub-groups was calculated using Cohen’s d and 
results are presented as either a “small” or a “medium” effect based on Cohen’s criteria, where a 
Small effect = 0.2; Medium effect = 0.5; large effect = 0.8 [35]. The dominant and recessive 
models were carried out with the dominant model comparing the GG genotype with GA and AA, 












possible to carry out an analysis of codominance as the articles did not consistently present the 




3.1 Study characteristics 
A total of 850 articles were identified from the initial search (Fig. 1) with 291 articles from Web 
of Science, 241 from Pub med, 309 from EMBASE and 9 from the Cochrane library. Articles that 
were either not relevant, in that they did not include relevant data or were not in English or were 
not studied in the human population, were excluded leaving 29 relevant articles for further 
scrutiny.  Of these articles, 10 were excluded based on the following criteria: either the data were 
not from the original source (e.g. meta-analysis) (n=4), the participants were taking statins (n=1), 
subjects younger than 18 years (n=3) were excluded, the genotype data was presented as inter-
quartile range, or there was concern about inaccuracies and/or inconsistencies in the presentation 
of the data (n=1) or only interquartile genotype data was reported (n=1). Of the remaining 19 
articles, some included more than one data set and therefore the final selection contained 28 data 














Web of Science n=291 
Pub med n= 241 
Embase n=309 
Cochrane Library n= 9 
Articles identified by searching database 
(850). 
 Articles excluded total n=821 
do not satisfy inclusion criteria n=812 
Not in English n=4 
Not in human populations n=5 
 
  
Articles obtained for further review n=29  
  
 Articles excluded n= 10 
Meta-analysis study n=4 
Subjects taking statins n=1 
Subjects younger than 18 years n=3 
Interquartile genotype data only n=1 
Inaccuracies in genotype data n=1 
 
  
Articles included for meta-analysis n=19 
[28 data sets] 
 
 
Figure 1: Flow chart showing the systematic screening and selection process of articles used 
in this study.   
 
Articles published between 2001 and 2018 included data relating to subjects from North, South 
and Central America, the Middle East, Europe, Asia and from an ethnically mixed population 
group (Table 1).  The weighted mean age for the total group was 48years (± 9.8) although age data 
was not available for the Ambye et al. study [17].  The study participants were separated for some 
of the analyses based on whether they were from an Asian or a non-Asian background and the 
weighted mean age did not change (48 years) with a weighted standard deviation of 14.35 and 
16.26 for the Asian and the non-Asian group respectively. 
The data sets were combined across the studies and values of TC, HDL, LDL, TG, BMI and FPG 












AA was then determined, and a summary of the complete data analysis is presented in Table 2.  
The data is presented as either wildtype (GG) or carrier (GA or AA) and analysis was based on the 
dominant or the recessive model.  The data available from the articles selected were not in an 
appropriate format to carry out determination of co-dominance as the number of articles with data 
separating the GA and AA genotypes was not of sufficient power to conduct the analysis.  The 
effect size of the lipid profile data for the two groups was determined using Cohen’s criteria: 
where a “small effect” was evident for HDL and TG at -0.26, -0.17 respectively; with a medium 










Table 1: Characteristics of the studies selected for meta-analysis Articles selected include 28 data sets representing 5236 subjects. Ethnic origin of subjects identified as follows: Country 
(either Asian (A) or Non-Asian (Non-A); Mixed (includes samples includes Canada, Finland, Sweden, Norway, Israel, Spain) 








Year County of origin 
(Ethnic origin) 




FPG mmol/L)      
Mean (SD) 
TC (mmol/L)     
Mean (SD) 










2001 Denmark (Non-A) 198 25.23(3.86) 5.1(0.44) 5.47(1.10) 1.43(0.40) NA 1.18(0.68) 
Ek 2 et al.  [36] 134/1
59 
61(1) 2001 Denmark (Non-A) 293 26.15(3.68) 5.15(0.50) 6.25(0.99) 1.49(0.44) NA 1.34(0.78) 
Andrulionyte et al.  [26] 387/3
83 
55(8) 2004 Mixed population 770 30.76(3.98) 6.26(0.53) 5.67(1.01) 1.19(0.32) 3.60(0.90) 2.00(1.10) 
Ambye et al.  [17] 1108/
1147 
NA 2005 Denmark (Non-A) 2255 25.83(4.14) 4.79(0.50) 6.14(1.10) 1.41(0.40) 4.04(1.00) 1.40(0.99) 
Vohl 1 et al.  [31] NA 40(10) 2005 Canada (Non-A) 173 53.14(10.08
) 
5.48(0.80) 5.04(0.94) 1.20(0.32) 3.00(0.81) 1.86(0.95) 
Vohl 2 et al.  [31] NA 48(9) 2005 Canada (Non-A) 84 52.21(9.96) 8.06(2.84) 4.76(0.97) 1.14(0.33) 2.63(0.87) 2.30(1.19) 
Hui 1 et al.  [37] NA 51(11) 2008 China (A) 96 24.81(1.99) 5.43(1.14) 5.69(2.62) 2.00(0.89) 3.60(0.65) 3.49(1.69) 
Hui 2 et al.  [37] NA 51(11) 2008 China (A) 96 24.37(2.09) 4.93(0.64) 5.83(1.17) 2.13(1.06) 3.27(0.68) 2.13(1.54) 
Zhang 1 et al.  [27] NA 62(5) 2007 China (A) 282 23.62(3.19) NA 4.57(1.59) 1.58(0.42) 2.29(1.45) 1.62(1.08) 
Zhang 2 et al.  [27] NA 64(6) 2007 China (A) 263 24.10(2.54) NA 5.34(1.48) 1.50(0.35) 2.99(1.16) 1.84(1.44) 
Goyenechea et al.  [28] 93/87 35(6) 2008 Spain  
(Non-A) 
180 31.20(3.06) 5.06(0.41) 5.32(0.94) 1.36(0.340 3.43(0.82) NA 
Okauchi et al.  [32] 74/81 62(10) 2008 Japan (A) 155 24.91(5.39) 9.17(2.63) 5.29(1.07) 1.25(0.34) NA 1.64(0.91) 
Chae 1 et al.  [38] NA 26(6) 2010 South Korea (A) 184 22.15(4.83) 4.90(0.89) 4.53(1.20) 1.55(0.43) NA 1.23(0.73) 
Chae 2 et al.   [38] NA 29(4) 2010 South Korea (A) 256 20.25(2.89) 4.95(0.45) 4.37(0.68) 1.65(0.33) NA 0.78(0.28) 
Niktin 1 et al.  [29] NA 56(9) 2010 Russia  
(Non-A) 
132 29.25(6.48) NA 4.87(0.92) 1.68(0.18) 2.84(0.25) 1.45(0.09) 
Niktin 2 et al.  [29] NA 59(8) 2010 Russia (Non-A) 313 28.38(5.14) NA 5.58(0.97) 1.44(0.20) 3.75(0.36) 1.65(0.14) 
Zhang et al.  [27] 125/1
16 
49(10) 2010 China (A) 241 24.96(3.2) 8.92(3.47) 4.91(1.95) 1.33(0.70) 2.88(1.08) 3.00(3.33) 
Geloneze et al.  [39] 47/8 37(10) 2012 Brazil (NA) 55 44.47(5.52) 5.15(1.21) 4.50(0.85) 1.11(0.28) 2.84(0.66) 1.48(0.37) 
Miraezi et al.  [24] NA 37(12) 2012 Iran (Non-A) 229 30.25(6.54) 5.69(1.86) 4.42(0.79) 1.15(0.27) 2.47(0.59) 1.37(0.63) 
Nishida et al.  [40] Males 
only 










Shokouhi 1 et al.  [41] 82/91 53(10) 2015 Iran (Non-A) 173 26.91(4.35) NA 4.63(1.09) 3.01(0.70) 3.04(0.80) 1.65(0.46) 
Shokouhi 2 et al.  [41] 73/10
0 
55(11) 2015 Iran (Non-A) 173 28.81(4.88) NA 5.13(1.07) 0.93(0.24) 3.41(0.94) 2.07(0.47) 
Vazques-Delmercado 1 
et al.  
[14] NA 38(14) 2015 Mexico (Non-A) 153 22.45(1.66) 4.83(0.62) 4.45(0.96) 1.03(0.43) 2.73(0.93) 1.30(0.73) 
Vazques-Delmercado 2 
et al.  
[14] NA 38(14) 2015 Mexico (NA) 144 27.39(1.43) 5.31(0.68) 4.96(1.05) 0.93(0.34) 2.92(0.94) 1.89(1.17) 
Vazques-Delmercado 3 
et al.  
[14] NA 38(14) 2015 Mexico (Non-A) 78 34.15(3.27) 5.38(0.75) 4.96(0.81) 0.97(0.37) 3.02(0.69) 1.72(0.90) 
Tai et al.  [42] 56/62 30(10) 2016 Taiwan (A) 177 41.88(7.56) 5.85(1.74) 5.09(1.01) 1.21(0.28) 3.41(0.94) 1.69(1.16) 
Tobina et al.  [43] 49/70 71(7) 2016 Japan (A) 119 23.81(3.25) NA 5.46(0.79) 1.56(0.37) 3.34(0.74) 1.21(0.7) 
Ramos-Lopez et al. [44] NA NA 2018 Spain  
(Non-A) 













No differences were evident for any of the components of the lipid profile (TC, HDL, LDL, TG) 
when the total population was analysed (p>0.05 see table 2). However, when the studies were 
grouped based on participants representing an Asian or a non-Asian population a significant effect 
was observed in the total cholesterol level for the non-Asian group (p<0.05) with lower levels of 
TC for participants with AA genotype in comparison to combined “GG+GA” genotypes using a 
recessive genetic model (WMD = -0.11, 95% CI = -0.21 to -0.02) (Table 2, Figure 2a). No 
significant difference in TC levels was observed in “AA” genotype in comparison to “GG+GA” 














Figure 2. Forest plot showing graphical representation of studies identified from meta-analysis of Gly482Ser 
variant of PPARGC1A of total cholesterol (TC) levels under the recessive genetic model using fixed effect 
model with a comparison with Non- Asian and Asian groups.  At the bottom of the Forest plot the scale used 
to accommodate the range of confidence interval is included e.g. -1.22 - +1.22. 
 
Heterogeneity between groups: p = 0.130
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Table 2: Summary of meta-analysis of Gly482Ser variant of PPARGC1A with lipid profile fasting blood glucose and body mass index 



















(GG vs. GA+AA) Yes Rn -0.02 0.13 -0.01 0.16 -0.03 0.37 
R 
(AA vs. GG+GA) Yes Rn -0.02 0.38 -0.03 0.90 0.00 0.33 
LDL 
D 
(GG vs. GA+AA) Yes Rn 0.01 0.89 -0.03 0.63 0.03 0.67 
R 
(AA vs. GG+GA) No F -0.05 0.11 -0.09 0.26 -0.04 0.20 
TG 
D 
(GG vs. GA+AA) Yes Rn 0.01 0.74 0.04 0.26 0.00 0.92 
R 
(AA vs. GG+GA) No F -0.02 0.35 -0.02 0.65 -0.02 0.41 
TC 
D 
(GG vs. GA+AA) Yes Rn 0.05 0.32 -0.01 0.92 0.08 0.15 
R 
(AA vs. GG+GA) No F -0.07 0.07 0.00 0.95 -0.11 ≤0.05 
FPG 
D 
(GG versus GA+AA) Yes Rn -0.01 0.69 -0.03 0.64 -0.01 0.84 
R 
(AA versus GG+GA) No F -0.08 ≤0.001 -0.06 0.14 -0.09       ≤0.001 
BMI 
D 
(GG versus GA+AA) No F 0.13 0.1 0.32 ≤0.05 0.04 0.68 
R 
(AA versus GG+GA) No F -0.08 0.54 -0.08 0.12 0.08 0.65 
 
ꭞ D= dominant model R = Recessive model; No = heterogeneity statistically significant; Yes = heterogeneity statistically not significant.ꭞꭞ Rn = random, F = fixed; ;  
§ WMD = weighted mean difference. BMI = body mass index; HDL = high-density lipoprotein; LDL= low-density lipoprotein; TG = triglyceride; TC = total cholesterol; FPG = Fasting plasma 













In the total group the FPG data demonstrated that there was an association with genotype 
(p<0.001) (Table 2 Fig 3) with a significantly reduced FPG level in AA genotypes in comparison 
with GG+GA genotypes indicating a protective effect of the minor allele (p≤0.001) (Table 2; Fig 
3a).  This was also evident in the non-Asian group (p≤0.001) (WMD = -0.08, CI: - 0.13 to -0.03) 
(Table 2, Fig. 3b), while for the Asian population there was no support for a protective effect from 
















Figure 3. Forest plot showing graphical representation of studies identified from meta-analysis of Gly482Ser 
variant of PPARGC1A fasting plasma glucose (FPG) identified from meta-analysis using the fixed effect 
model under recessive model with the total population (a) and with the Asian and non-Asian subgroups (b). 
At the bottom of the Forest plot the scale used to accommodate the range of confidence interval is included 
e.g. -2.64 – +2.64.  
Overall  (I-squared = 4.6%, p = 0.401)
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Total population studies demonstrated that there was no association with BMI and genotype 
(p=0.1 and p=0.54 under the dominant and the recessive model respectively) (Table 2).  However, 
the dominant model data generated from the Asian studies demonstrated a significantly higher 
BMI for “GG” genotype in comparison to “GA+AA” genotype group under the dominant genetic 
model (WMD = 0.32, CI: 0.04 to 0.60, p- <0.05 (Table 2), but this was not evident within the non-
Asian studies (p=0.68) (Table 2). No significant heterogeneity was observed in either the non-
Asian (I2 = 0%, p = 0.93) or the Asian populations with respect to BMI (I2 = 0 %, p = 0.66) (Fig. 
4). BMI for the Asian group was found to be significantly  
The protection conferred by the minor allele for a lower BMI is particularly relevant to the Asian 
population given the ethnic-specific criteria for the diagnosis of metabolic syndrome [1]; namely a 
reduced waist circumference is advised for the Asian population for diagnosis of metabolic 















Figure 4. Forest plot illustrating body mass index levels (BMI) identified from meta-analysis of Gly482Ser 
variant of PPARGC1A using the fixed effect model under the dominant genetic model with a comparison of 
Non- Asian and Asian groups. At the bottom of the Forest plot the scale used to accommodate the range of 
confidence interval is included e.g. -6.19 - +6.19. 
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The present study has shown that the Gly482Ser variant of PPARGC1A gene is significantly 
associated with BMI in Asian populations under the dominant genetic model.  Furthermore, the 
SNP is significantly associated with total cholesterol in non-Asians under the recessive genetic 
model and was significantly associated with fasting plasma glucose in the total population 
(including Asian and Non-Asian) and in the non-Asian population. 
Many emerging lines of evidence suggest an important role of PPARGC1A in lipid metabolism [4, 
5, 45, 46, 47] especially in skeletal muscle [6] and liver [3]. PPARGC1A Gly482Ser is one of the 
most studied variants and some recent studies indicated its association with lipid levels [14, 23, 
43, ]. To our knowledge, this is the first time a meta-analysis of the association of this SNP with 
lipid profile has been conducted. Other components of metabolic syndrome in humans have been 
included to address conflicting results from the literature.  
In this study, using the dominant genetic model, the BMI of those individuals with the GG 
genotype is significantly higher in Asian subgroups. Taken individually the articles including the 
Asian data in the meta-analysis do not show any significant difference under either the dominant 
or recessive model but the power has been improved by combining data in the meta-analysis. In 
contrast, reports have indicated that the minor allele being associated with type 2 diabetes 
susceptibility [36], relative risk of obesity [47] insulin resistance [26] and reduced beta cell 
function [48 kleiner].     The association of this SNP with BMI in the Tongan population is evident 
where BMI was elevated under both a co-dominant and a dominant model [49].  The Tongan 
population have the Gly482Ser variant present at high frequency and may have been conserved 
within the population as a thrifty gene. However, it is clear that generalisations cannot be made as 
the minor allele of this SNP is associated with elevated body mass in Korean children [13] and 
non-diabetic overweight Chinese subjects [15].  
There are clearly a number of different variables that are important for the Gly482Ser genotype to 
contribute to the BMI profile.  The power of the present study with respect to BMI could have 
been improved as we excluded a number of articles with relevant BMI data as they did not include 
lipid levels as this was the prime focus of the study.  However, it does highlight an interesting 












differential diagnosis of metabolic syndrome with a lower BMI cut off point for individuals of 
Asian origin [1].   
The reduction of fasting plasma glucose levels in AA genotypes also has differential significance 
with the two population groups.  The analysis of the overall population and the non-Asian group 
indicated that the minor allele had a protective effect against elevated fasting glucose in the non-
Asian population but this was not evident in the Asian group.  Furthermore, the total cholesterol 
level was reduced in the non-Asian group with a similar protective effect of the homozygous 
recessive genotype.  The apparent protective effect of the minor allele (Ser) in the non-Asian study 
group is supported by studies that propose that the presence of the major allele (Gly) has been 
associated with reduced cardiorespiratory fitness in Japanese men [40].  
These studies have been conducted in different population groups that are defined by the primary 
aim of the respective studies such as type 2 diabetes, CAD (coronary artery disease), morbidly 
obese, obese, pre-obese, NAFLD (Non-alcoholic fatty liver disease) and the elderly age group.  
This could exacerbate the heterogeneity and thus confound the distinction between the Asian and 
non-Asian group. While the heterogeneity of the population group may contribute to the study 
outcome, it is also evident that the ubiquitous nature of PPARGC1A in such fundamental 
processes as energy metabolism, lipid regulation, oxygen uptake, adipogenesis and insulin 
signalling presents a highly complex system that may also be a source of heterogeneity.  Thus, 
specific follow up of outcomes demonstrating differential effects between non-Asian and Asian 
population and the apparent protective effect of the minor allele in the Asian group warrants 
further scrutiny.  Epigenetic changes may contribute to this dichotomy [50, 51] and may explain 
the variation seen in distinct ethnic population groups as evident in the outcomes from the present 
study.  
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Supplementary Table 1: Components of metabolic syndrome as defined from the National 
Cholesterol Education Programme, Adult Treatment Panel III, EGSIR (NCEP ATP III 
modified) [1] M (male); F (female) 
 
Impaired fasting glucose ≥ 5.6 mmol/L or diagnosed with diabetes. 
Waist circumference European ≥94 cm (M) or ≥80cm (F), 
 United States ≥ 102 (M) or ≥88 (F), South Asian ≥90 cm (M) 
or ≥80cm (F), Chinese ≥85 cm (M) or ≥80cm (F), Japanese ≥85 
cm (M)or ≥90 cm (F) 
Blood pressure ≥130/85mmHg or medication 
Triglycerides s≥1.7mmol/l or medication,  
Cholesterol HDL-C <1.0mmol/l (M) and <1.30mmol/l (F) or on medication 
 
 
Supplementary Table 2:  Search term used for systematic review of Peroxisome proliferator 
activator receptor type 1 alpha and the Gly482Ser polymorphism 
 
Data base Terms used Number of 
articles identified 
Web of Science ("Peroxisome proliferator activator receptor gamma 
coactivator 1" or PPARGC1A or PGC-1 or PGC-
1alpha or PGC1alpha) AND (Polymorphism or 
Gly482Ser or “rs8192678”)  
291 
Pub med  (“Peroxisome proliferator activator receptor gamma 
coactivator 1” or “PPARGC1A” or “PGC-1” or 
“PGC-1alpha” or “PGC1alpha”) and 
“polymorphism” or “Gly482Ser” or “rs8192678”  
241 
Embase (“Peroxisome proliferator activator receptor gamma 
coactivator 1” or “PPARGC1A” or “PGC-1” or 
“PGC-1alpha” or “PGC1alpha”) and 
“polymorphism” or “Gly482Ser” or “rs8192678” 
309 
Cochrane (“Peroxisome proliferator activator receptor gamma 
coactivator 1” or “PPARGC1A” or “PGC-1” or 
“PGC-1alpha” or “PGC1alpha”) and 
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Meta-analysis demonstrates Gly482Ser variant of PPARGC1A is 
associated with components of metabolic syndrome within 
Asian populations 
Prabhakar Bhatta, Giovanna Bermano, Hector C Williams and 
Rachel M Knott* 
HIGHLIGHTS: 
 
• This is the first meta-analysis where cholesterol has been used as an indicative 
element in the data search strategy for this variant; 
• The work demonstrates a genetic distinction at the level of the BMI between the Asian 
and non-Asian population groups (important criteria in the management of metabolic 
syndrome and diabetes);  
• the AA genotype group showed significantly lower levels of total cholesterol (TC) 
compared to GG+GA genotype using the recessive model in the non-Asian population 
group that was not evident in the Asian sample. 
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